Plain-English translation of NCT07172360 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether can help people with active ankylosing spondylitis — a condition that causes painful inflammation in the spine and joints. The researchers want to learn if this medication is safe and effective by comparing it to a placebo (a pill with no active ingredient). Some participants will receive different doses of the medication, while others will receive placebo, to find the best dose that works.
Ankylosing spondylitis can severely limit movement and quality of life for many people. This trial exists to see whether this medication offers a new treatment option that could reduce pain and inflammation better than what's currently available.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication at a low dose, the medication at a high dose, or a placebo — neither you nor the study staff will know which one you receive. You'll visit the clinic multiple times to take your assigned tablets, have blood tests, and answer questions about how you're feeling. The study compares how well the two doses of medication work against placebo to determine safety and effectiveness.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Enrollment target
~420 participants
Started
December 2025
Primary completion
August 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
xiaojuan lai
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.